BASKING RIDGE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Millennium
Biotechnologies, Inc., a wholly owned subsidiary of Millennium
Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), reports continued
success of their international distribution partnership for the Resurgex(R)
line of products in Greece. Since first delivering product to Nutrimedica
in April 2006 overall sales in the Greek Market have increased
approximately 40% from $30,000 in 2006 to $50,000 in 2007. A successful
entry of a U.S. product into the Greek market depends on proper selection
of a qualified distributor in Greece, which is knowledgeable of the local
market and regulations. The distributor must be capable of developing a
proper relationship with the distribution chain of medical institutions,
practitioners and proper retail outlets in the medical marketplace. For the
past 22 months Millennium has working with Nutrimedica, a well known
distributor of nutritional products, in Athens. It has already imported and
distributed Resurgex(R) products to hospitals, pharmacies, and direct to
patients. Nutrimedica reports that the introduction of Resurgex products
has been well received and sales have been steadily increasing. The steady
growth has been encouraging due to the fact that no marketing dollars have
been allocated to build brand awareness in the marketplace.

About Millennium:

Millennium's three proprietary, marketed products, which form the
Company's Resurgex(R) Continuum of Care, include Resurgex Select(R),
Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole
foods-based, calorically dense, high-protein nutritional formula developed
for cancer patients undergoing chemotherapy or radiation treatments.
Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional
supplements rich in antioxidants that provide nutritional support
post-treatment. Millennium is also recently developed a Surgex(R) sports
nutrition formula, clinically proven to address the nutritional concerns of
both professional and amateur elite athletes. These athletes often
experience similar symptoms post-workout to those battling
immunocompromised conditions, such as fatigue, loss of lean muscle,
oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and
operating results, future growth in R&D programs, potential applications of
the Company's technology, opportunities for the Company, and any other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words "will," "believes," "plans," "anticipates," "expects,"
"estimates," and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that
could cause actual results or events to differ materially from those
indicated by such forward- looking statements including: limited operating
history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of the Company's
intellectual property, and economic conditions generally. Additional
information on potential factors that could affect results and other risks
and uncertainties are detailed from time to time in the Company's periodic
reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with
the Securities and Exchange Commission ("SEC").

(Date:12/8/2016)... ALAMEDA, Calif. , Dec. 8, 2016 Singulex, ... Single Molecule Counting technology, entered into a license and ... in serving science. The agreement provides Singulex access to ... Europe is used to diagnose ... the United States to aid in assessing ...